The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CD19 targeted chimeric antigen receptor T (CAR-T) cell immunotherapy has demonstrated significant anti-leukemia activity in pediatric patients with relapsed/refractory acute lymphocytic leukemia: A multicentre study in China.
 
Lei Xiao
Employment - Innovative Cellular Therapeutics Co
Leadership - Innovative Cellular Therapeutics Co
Stock and Other Ownership Interests - Innovative Cellular Therapeutics Co
Honoraria - Innovative Cellular Therapeutics Co
Patents, Royalties, Other Intellectual Property - Innovative Cellular Therapeutics Co
 
Yongmin Tang
Research Funding - Innovative Cellular Therapeutics Co (Inst)
 
Xiaofan Zhu
Research Funding - Innovative Cellular Therapeutics Co (Inst)
 
Jing Chen
Research Funding - Innovative Cellular Therapeutics Co (Inst)
 
Zhao Wu
Employment - Innovative Cellular Therapeutics Co
Leadership - Innovative Cellular Therapeutics Co
Stock and Other Ownership Interests - Innovative Cellular Therapeutics Co
Honoraria - Innovative Cellular Therapeutics Co
Research Funding - Innovative Cellular Therapeutics Co
Patents, Royalties, Other Intellectual Property - Innovative Cellular Therapeutics Co